THERAPY DOSSIER · th-fb4ed728f681

Putrescine combined with Schwann cell implantation

Biologic · Putrescine (polyamine); no curated ChEMBL mechanism record

Evidence & regulatory context

Mechanism: Putrescine (polyamine); no curated ChEMBL mechanism record
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Preclinical/no trial
ChEMBL record: CHEMBL46257 ↗
ChEMBL max phase: 3 / 4 (development scale, not regulatory approval)
Synonyms: Putrescine; 1,4-diaminobutane
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26550496 ↗2015Reported benefit

Acute Putrescine Supplementation with Schwann Cell Implantation Improves Sensory and Serotonergic Axon Growth and Functional Recovery in Spinal Cord Injured Rats.

RatSpinal cord injuryContusionFischer (F344)femalen = 34 rats in total: Schwann cells plus vehicle n = 11, plus a…putrescine by subcutaneous Alzet 2001 osmotic minipump; Schwann cells by intraspinal injection into the contusion epicentre at 1 mm depthputrescine 100 mM infused at 0.5 microlitres/h; Schwann cel…putrescine started either within 30 min of injury or 1 week after injury; Schwa…

Model: Moderate T9 contusion spinal cord injury using the MASCIS weight drop device, 10 g rod from 12.5 mm, after T8 laminectomy

Adding putrescine to Schwann cell implants increased implant size with delayed delivery, increased serotonergic and CGRP axon growth and improved BBB score and subscore for both timings, with reduced grid walk footfalls only after acute delivery.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.88. Machine-extracted fields require source verification.

Loading the evidence…